Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
1.500
-0.010 (-0.66%)
At close: Oct 29, 2025, 4:00 PM EDT
1.500
0.00 (0.00%)
After-hours: Oct 29, 2025, 5:19 PM EDT
Telomir Pharmaceuticals Employees
As of December 31, 2023, Telomir Pharmaceuticals had 9 total employees, including 1 full-time and 8 part-time employees.
Employees
9
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,786,536
Market Cap
50.75M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TELO News
- 6 days ago - Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo - Accesswire
- 8 days ago - Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth - Accesswire
- 15 days ago - Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer - Accesswire
- 20 days ago - Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug - Benzinga
- 20 days ago - Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells - Accesswire
- 22 days ago - Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance - Accesswire
- 5 weeks ago - Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies - Accesswire
- 7 weeks ago - Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy - Accesswire